Content
Frontiers of Medicine >> 2019, Volume 13, Issue 3 doi: 10.1007/s11684-019-0689-5
Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl
. Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.. Department of Gastroenterology, the Second Affiliated Hospital of Harbin Medical University, Harbin 150010, China.. Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
Abstract
Keywords
portal hypertension ; cirrhosis ; urotensin II ; palosuran ; hepatic stellate cell
Content